Selected article for: "lopinavir hydroxychloroquine and lung opacity"

Author: Song, Jehun; Kang, Seongmin; Choi, Seung Won; Seo, Kwang Won; Lee, Sunggun; So, Min Wook; Lim, Doo-Ho
Title: Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs
  • Cord-id: j3sp3dq9
  • Document date: 2020_4_20
  • ID: j3sp3dq9
    Snippet: In December 2019, numerous coronavirus disease 2019 (COVID-19) cases were reported in Wuhan, China, which has since spread throughout the world. However, its impact on rheumatoid arthritis (RA) patients is unknown. Herein, we report a case of COVID-19 pneumonia in a 61-year-old female RA patient who was receiving conventional disease-modifying antirheumatic drugs (cDMARDs). The patient presented with a 4-day history of myalgia and febrile sensation. COVID-19 was confirmed by real-time polymerase
    Document: In December 2019, numerous coronavirus disease 2019 (COVID-19) cases were reported in Wuhan, China, which has since spread throughout the world. However, its impact on rheumatoid arthritis (RA) patients is unknown. Herein, we report a case of COVID-19 pneumonia in a 61-year-old female RA patient who was receiving conventional disease-modifying antirheumatic drugs (cDMARDs). The patient presented with a 4-day history of myalgia and febrile sensation. COVID-19 was confirmed by real-time polymerase chain reaction (PCR). Chest X-ray showed increased opacity on the right lower lung area, and C-reactive protein level was slightly elevated. The patient was treated with antiviral agents (lopinavir/ritonavir), and treatment with cDMARDs was discontinued except hydroxychloroquine. Her symptoms and laboratory results gradually improved. Three weeks later, real-time PCR for COVID-19 showed negative conversion, and the patient was discharged without any complications.

    Search related documents:
    Co phrase search for related documents
    • abnormal finding and admission mechanical ventilation: 1, 2
    • abnormal finding and admission mechanical ventilation require: 1, 2
    • abnormal finding and lopinavir ritonavir: 1
    • acid folic and acute respiratory syndrome: 1, 2, 3, 4
    • acid folic and lopinavir ritonavir: 1
    • acute respiratory syndrome and admission 10 day: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory syndrome and admission day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and admission mechanical ventilation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and admission mechanical ventilation require: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and admission patient respiratory symptom: 1
    • acute respiratory syndrome and liver function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and local clinic: 1
    • acute respiratory syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lopinavir ritonavir administration: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and lopinavir ritonavir treat: 1, 2, 3, 4, 5
    • admission 10 day and lopinavir ritonavir: 1
    • admission day and liver function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • admission day and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • admission day and lopinavir ritonavir treat: 1